Collaboration opportunities with Daiichi Sankyo in early stage research and technology
Daiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas.
One Nucleus is delighted to be working with Daiichi Sankyo and the Department for International Trade Japan Team to bring you a free online seminar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:
- Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
- Novel drug delivery technologies to cancer cells or brain after systemic administration
- Novel target or cancer-specific antigen for antibody in oncology
10.00 – Collaboration Opportunities with Daiichi Sankyo in Early Stage Research and Technology
Kunihiko Fujii, Manager, BD & Licensing, Daiichi Sankyo
10.45 – Q&A
11.00 – Close
Registration is free and the limited places will be allocated on a first-come-first-served basis.
Please note, all registrations are subject to the approval of the sponsor. You will be informed if your registration has been unsuccessful within 2 working days of registering online for the event.
For more information, please contact email@example.com